GATA1 and chronic myelogenous leukemia, BCR-ABL1 positive: CBP/p300 bromodomain inhibition blocks GATA1 and MYC oncogene expression and induces chronic myeloid leukemia and lymphoma cell cycle arrest and growth inhibition 72.